12900 Results (Page 291 of 516)
All Market Research Reports
Brazil Alzheimer’s Disease Drugs Market Analysis
Brazil's Alzheimer’s disease drugs market was valued at $386 Mn in 2022 and is estimated to expand at a CAGR of 9.42% from 2022-30 and will reach $792 Mn in 2030. One of the main reasons propelling the growth of this market is government support technologies and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Abbvie, AstraZeneca, Aspen, Bristol Myers Squibb, Chiesi Farmaceutici, Daiichi Sankyo Company, Eisai Co., Eurofarma, Ferring, Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Ono Pharmaceutical Co., Pfizer and Teva Pharmaceutical among others.
Canada Alzheimer’s Disease Drugs Market Analysis
Canada's Alzheimer’s disease drugs market was valued at $1.23 Bn in 2022 and is estimated to expand at a CAGR of 8.42% from 2022-30 and will reach $2.35 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Pfizer, Biogen, Eli Lilly and Company, Novartis International AG, Merck & Co, AstraZeneca, Roche Holding AG, Johnson & Johnson, AbbVie, and Sanofi among others.
France Alzheimer’s Disease Drugs Market Analysis
The France Alzheimer’s Disease Drugs market was valued at $424 Mn in 2022 and is estimated to expand at a CAGR of 7.42% from 2022-30 and will reach $752 Mn in 2030. One of the main reasons propelling the growth of this market is government support, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Alexion Pharma, Takeda Pharmaceuticals, Biogen, Daiichi Sankyo Company, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Ono Pharmaceutical Co., Pfizer, and Teva Pharmaceutical among others.
Egypt Teleradiology Market Analysis
The Egypt Teleradiology market size was valued at $7 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 13.2% from 2022 to 2030 and will reach $ 18 Mn in 2030. The market is segmented by application, modality, technology solutions, and end user. The Egypt teleradiology market will grow due to advancements in technology, such as electronic medical records (EMRs) and picture archiving and communication systems (PACS), have made it easier to transmit and store medical images securely. The key market players are Alborg Laboratories & Radiology Services, Alfa Labs, Cairo Scan Radiology & Labs, Egypt Radiology Group, Ebtisama Radiology, MedMark Teleradiology, Mena Medical Solutions, Radiology Group, Telemedica Egypt and others.
Germany Alzheimer’s Disease Drugs Market Analysis
Germany's Alzheimer’s Disease Drugs market was valued at $564 Mn in 2022 and is estimated to expand at a CAGR of 6.62% from 2022-30 and will reach $942 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer drugs, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are AbbVie, AstraZeneca, Boehringer Ingelheim, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Pfizer among others.
Japan Alzheimer’s Disease Drugs Market Analysis
Japan's Alzheimer’s disease drugs market was valued at $958 Mn in 2022 and is estimated to expand at a CAGR of 8.92% from 2022-30 and will reach $1899 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Daiichi Sankyo Company, Eisai Co., Eli Lilly and Company, Johnson and Johnson., Novartis AG, Pfizer, Takeda Pharmaceutical, Chugai Pharmaceutical, Astellas Pharma, Otsuka Holdings Co, Shionogi & Co among others.
North America Alzheimer’s Disease Drugs Market Analysis
North America Alzheimer’s disease drugs market was valued at $7.71 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.42% from 2022 to 2030 and will reach $13.67 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies and the development of drugs, the aging population. The market is segmented by drug classes and by distribution channels. Some key players in this market are Amgen, Eisai Co., Eli Lilly and Company, Roche and Johnson, and Johnson among others.
US Alzheimer’s Disease Drugs Market Analysis
The US Alzheimer’s disease drugs market was valued at $6.48 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.42% from 2022 to 2030 and will reach $10.65 Bn in 2030. One of the main reasons propelling the growth of this market is government support, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are AstraZeneca, Biogen, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Ono Pharmaceutical Co., Pfizer and Teva Pharmaceutical among others.
Norway Neurology Device Market Analysis
Norway's Neurology devices market size was valued at $xx Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of xx% from 2022 to 2030 and will reach $xx Bn in 2030. The market for neurology devices in Norway is expanding as a result of the prevalence of neurological diseases including Alzheimer's, Parkinson's, and epilepsy is rising in Norway as the population ages. The market is segmented by product type and by the end user. Some key players in this market include Medistim, Norgesplaster, Medtronic, Abbott Laboratories, Boston Scientific, and Stryker.
Brazil Anemia Drugs Market Analysis
Brazil's Anemia drugs market was valued at $400 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.9% from 2022 to 2030 and will reach $850 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Cristalia Pharma, Ache, EMS Pharma, Eurofarma, BioLab Pharma, Roche, and Pfizer among others.
China Anemia Drugs Market Analysis
China's Anemia drugs market was valued at 1.28 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.4% from 2022 to 2030 and will reach $2.83 Bn in 2030. One of the main reasons propelling the growth of this market is an increase in income and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Roche, Novartis, Sanofi, Shanghai Pharmaceuticals, Sinopharm Group, Jiangsu Hengrui Medicine, and Guangzhou Baiyunshan Pharmaceutical among others.
Europe Anemia Drugs Market Analysis
Europe's Anemia drugs market was valued at $3.04 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.64% from 2022 to 2030 and will reach $5.47 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Amgen, AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson, Pfizer, and Sanofi among others.
France Anemia Drugs Market Analysis
France's Anemia drugs market was valued at 439 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.9% from 2022 to 2030 and will reach $807 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies and the increase in chronic diseases. The market is segmented by type, drug, and distribution channel. Some key players in this market are Amgen, Aspen, AstraZeneca, Bristol Myers Squibb, Chiesi Farmaceutici, Curium, and Daiichi Sankyo Co.
Germany Anemia Drugs Market Analysis
Germany's Anemia drugs market was valued at $585 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.1% from 2022-30 and will reach $1012 Mn in 2030. One of the main reasons propelling the growth of this market is an increase in chronic illness and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are 1A Pharma, 3B Pharmaceuticals, Abbott, AbbVie Germany, Abnova, AbZ-Pharma, Accord Healthcare, Amgen, and Pfizer among others.
Global Anemia Drugs Market Analysis
The Global Anemia drugs market was valued at $15.98 Bn in 2022 and is estimated to expand at a CAGR of 8.9% from 2022-30 and will reach $31.6 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pieris Pharmaceuticals, GlaxoSmithKline, Amgen, Bayer AG, Biocon, Takeda Pharmaceutical, Sanofi, and bluebird bio among others.
India Anemia Drugs Market Analysis
India's Anemia drugs market was valued at $291 Mn in 2022 and is estimated to expand at a CAGR of 11.9% from 2022-30 and will reach $714 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Alkem Laboratories among others.
Italy Anemia Drugs Market Analysis
Italy's Anemia drugs market was valued at $384 Mn in 2022 and is estimated to expand at a CAGR of 8.4% from 2022-30 and will reach $731 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Menarini, Chiesi, Angelini, Bracco, Roche, and Amgen among others.
Latin America Anemia Drugs Market Analysis
The Latin America Anemia drugs market was valued at $719 Mn in 2022 and is estimated to expand at a CAGR of 9.9% from 2022-30 and will reach $1530 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pfizer, Novartis, Amgen, Roche, AstraZeneca, Takeda Pharmaceutical, Sanofi, and Johnson & Johnson among others.
Spain Anemia Drugs Market Analysis
Spain's Anemia drugs market was valued at $308 Mn in 2022 and is estimated to expand at a CAGR of 7.9% from 2022-30 and will reach $567 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Opko Health, Arafarma Group, Rolabo Outsourcing, Brill Pharma, Persan Pharma, and Sanofi among others.
US Anemia Drugs Market Analysis
The US Anemia Drugs market was valued at $6.7 Bn in 2022 and is estimated to expand at a CAGR of 6.9% from 2022-30 and will reach $11.45 Bn in 2030. One of the main reasons propelling the growth of this market is an increase in chronic disease and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Amgen, Roche, Pfizer, Johnson & Johnson, Novartis, Takeda Pharmaceutical Co., Akebia Therapeutics, and FibroGen.
UK Anemia Drugs Market Analysis
The UK Anemia drugs market was valued at $415 Mn in 2022 and is estimated to expand at a CAGR of 6.9% from 2022-30 and will reach $709 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, driving demand for anemia drugs. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pfizer, Roche, Amgen, GlaxoSmithKline, Johnson & Johnson, Alcon Laboratories, FibroGen, Vifor Pharma Group, and Akebia Therapeutics among others.
Africa Alexipharmic Drugs Market Analysis
Africa's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 6.20% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The Africa Alexipharmic Drugs market will grow because there is a growing demand for safe and effective treatments for accidental poisoning. The key market players are Pharmacare (ZAF), Aspen Pharmacare (ZAF), Hikma Pharmaceuticals, Accord Healthcare, and others.
Brazil Alexipharmic Drugs Market Analysis
Brazil's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 5.70% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The Brazil Alexipharmic Drugs market will grow because the demand for alexipharmic drugs is largely driven by the incidence of poisoning cases in Brazil. The key market players are Instituto Butantan (BRA), Eurofarma (BRA), Sanofi, Pfizer Inc., AstraZeneca, and others.
Canada Alexipharmic Drugs Market Analysis
Canada Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 4.70% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The Canada Alexipharmic Drugs market will grow because As Canadians become more health-conscious, there is a growing demand for prescription medications to treat chronic conditions such as diabetes, depression, and high blood pressure. The key market players are Pfizer Inc., Merck & Co., Inc., Pfizer Inc., Bausch Health Companies Inc and others.
France Alexipharmic Drugs Market Analysis
France's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 3.70% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The France Alexipharmic Drugs market will grow because of growing people are also becoming more aware of the dangers of poisoning and how crucial it is to have quick access to antidotes in case of an emergency. The key market players are Sanofi (FRA), Seqens (FRA), Adocia (FRA), Laboratoires Chemineau (FRA), and others.